ITEM 2.  
Business Overview – a brief synopsis of our Company for the periods ended December 1, 2018 and December 2, 2017. 
Liquidity, Financial Position and Capital Resources – a discussion of our primary sources and uses of cash for the three and six month periods ended December 1, 2018 and December 2, 2017, and a discussion of changes in our financial position. 
Canvys provides customized display solutions serving the corporate enterprise, financial, healthcare, industrial and medical original equipment manufacturers markets. Our engineers design, manufacture, source and support a full spectrum of solutions to match the needs of our customers. We offer long term availability and proven custom display solutions that include touch screens, protective panels, custom enclosures, all-in-ones, specialized cabinet finishes and application specific software packages and certification services. Our volume commitments are lower than the large display manufacturers, making us the ideal choice for companies with very specific design requirements. We partner with both private label manufacturing companies and leading branded hardware vendors to offer the highest quality display and touch solutions and customized computing platforms. 
Healthcare manufactures, refurbishes and distributes high value replacement parts for the healthcare market including hospitals, medical centers, asset management companies, independent service organizations and multi-vendor service providers. Products include Diagnostic Imaging replacement parts for CT and MRI systems; replacement CT and MRI tubes; CT service training; MRI coils, cold heads and RF amplifiers; hydrogen thyratrons, klystrons, magnetrons; flat panel detector upgrades; and additional replacement solutions currently under development for the diagnostic imaging service market. Through a combination of newly developed products and partnerships, service offerings and training programs, we believe we can help our customers improve efficiency and deliver better clinical outcomes while lowering the cost of healthcare delivery. 
The second quarter of fiscal 2019 and fiscal 2018 each contained 13 weeks. 
Net sales for the second quarter of fiscal 2019 were $41.3 million, an increase of 5.7%, compared to net sales of $39.1 million during the second quarter of fiscal 2018. 
Gross margin decreased to 31.4% during the second quarter of fiscal 2019 compared to 34.2% during the second quarter of fiscal 2018. 
Selling, general and administrative expenses were $13.4 million, or 32.5% of net sales, for the second quarter of fiscal 2019 compared to $12.6 million, or 32.2% of net sales, for the second quarter of fiscal 2018. 
Operating loss during the second quarter of fiscal 2019 was $0.5 million compared to an operating income of $0.8 million in the second quarter of fiscal 2018.  
Net loss during the second quarter of fiscal 2019 was $0.3 million compared to net income of $1.7 million during the second quarter of fiscal 2018. Net income during the second quarter of fiscal 2018 included income of $1.5 million from discontinued operations. 
The first six months of fiscal 2019 and fiscal 2018 contained 26 and 27 weeks, respectively. 
Net sales for the first six months of fiscal 2019 were $85.5 million, an increase of 12.3%, compared to net sales of $76.1 million during the first six months of fiscal 2018. 
Gross margin decreased to 31.5% during the first six months of fiscal 2019 compared to 33.5% during the first six months of fiscal 2018. 
Selling, general and administrative expenses were $26.5 million, or 31.0% of net sales, for the first six months of fiscal 2019, compared to $24.9 million, or 32.8% of net sales, for the first six months of fiscal 2018. 
Operating income during the first six months of fiscal 2019 was $0.4 million compared to an operating income of $0.8 million in the first six months of fiscal 2018.  
Net income during the first six months of fiscal 2019 was $0.1 million compared to net income of $1.6 million during the first six months of fiscal 2018. Net income during the second quarter of fiscal 2018 included income of $1.5 million from discontinued operations. 
During the second quarter of fiscal 2019, consolidated net sales increased 5.7% compared to the second quarter of fiscal 2018. Sales for PMT increased 7.5%, sales for Canvys decreased 3.1% and sales for Healthcare increased 7.6%. The increase in PMT was mainly due to major growth in our new technology partners in RF and microwave components and power conversion and market share gains in the RF and microwave tube business. The decrease in Canvys was due to several large non-recurring orders that shipped in the second quarter of fiscal 2018. The increase in Healthcare was due to higher CT tube sales and increasing equipment sales, partially offset by lower part sales. 
During the first six months of fiscal 2019, consolidated net sales increased 12.3% compared to the first six months of fiscal 2018. Sales for PMT increased 13.4%, sales for Canvys increased 9.6% and sales for Healthcare increased 6.5%. The increase in PMT was due to specialty products manufactured in LaFox, market share gains in our legacy tube business and a strong increase in new technology partners in power conversion and RF and microwave components. The increase in Canvys was due to increased customer demand in our North American and European markets. The increase in Healthcare was due to higher CT tube sales and increasing equipment sales, partially offset by lower part sales. 
Consolidated gross profit decreased to $13.0 million during the second quarter of fiscal 2019 compared to $13.4 million during the second quarter of fiscal 2018. Consolidated gross margin as a percentage of net sales decreased to 31.4% during the second quarter of fiscal 2019 from 34.2% during the second quarter of fiscal 2018, primarily due to unfavorable product mix and manufacturing variances for PMT, unfavorable product mix and manufacturing variances for Healthcare, partially offset by favorable product mix and lower costs on selected products for Canvys. 
Consolidated gross profit increased to $26.9 million during the first six months of fiscal 2019 compared to $25.5 million during the first six months of fiscal 2018. Consolidated gross margin as a percentage of net sales decreased to 31.5% during the first six months of fiscal 2019 from 33.5% during the first six months of fiscal 2018, primarily due to unfavorable product mix and manufacturing variances for PMT, unfavorable product mix and manufacturing variances for Healthcare, partially offset by favorable product mix and lower costs on selected products for Canvys. 
PMT net sales increased 7.5% to $32.3 million during the second quarter of fiscal 2019 from $30.1 million during the second quarter of fiscal 2018. The increase was due to major growth in our new technology partners in power conversion and RF and microwave components as well as market share gains in the RF and microwave tube business. Gross margin as a percentage of net sales decreased to 31.3% during the second quarter of fiscal 2019 as compared to 34.1% during the second quarter of fiscal 2018, due to unfavorable product mix and manufacturing variances. 
PMT net sales increased 13.4% to $67.1 million during the first six months of fiscal 2019 from $59.2 million during the first six months of fiscal 2018. The increase included sales of specialty products manufactured in LaFox, market share gains in our legacy tube business and sales from new technology partners in power conversion and RF and microwave components. Gross margin as a percentage of net sales decreased to 31.5% during the first six months of fiscal 2019 as compared to 33.5% during the first six months of fiscal 2018, due to unfavorable product mix and manufacturing variances. 
Canvys net sales decreased 3.1% to $6.5 million during the second quarter of fiscal 2019 from $6.7 million during the second quarter of fiscal 2018 due to several large non-recurring orders that shipped in the second quarter of fiscal 2018. Gross margin as a percentage of net sales increased to 32.8% during the second quarter of fiscal 2019 as compared to 31.7% during the second quarter of fiscal 2018, due to favorable product mix and lower costs on selected products sold. 
Canvys net sales increased 9.6% to $13.7 million during the first six months of fiscal 2019 from $12.5 million during the first six months of fiscal 2018 due to increased customer demand in our North American and European markets. Gross margin as a percentage of net sales increased to 32.5% during the first six months of fiscal 2019 as compared to 29.5% during the first six months of fiscal 2018, due to favorable product mix and lower costs on selected products sold. 
Healthcare net sales increased 7.6% to $2.5 million during the second quarter of fiscal 2019 from $2.3 million during the second quarter of fiscal 2018 due to higher CT tube sales and increasing equipment sales, partially offset by lower parts sales. Gross margin as a percentage of net sales decreased to 29.4% during the second quarter of fiscal 2019 as compared to 42.6% during the second quarter of fiscal 2018 due to an unfavorable product mix and manufacturing variances. 
Healthcare net sales increased 6.5% to $4.7 million during the first six months of fiscal 2019 from $4.4 million during the first six months of fiscal 2018 due to higher CT tube sales and increasing equipment sales, partially offset by lower parts sales. Gross margin as a percentage of net sales decreased to 29.0% during the first six months of fiscal 2019 as compared to 45.5% during the first six months of fiscal 2018 due to an unfavorable product mix and manufacturing variances. 
Selling, general and administrative expenses increased to $13.4 million during the second quarter of fiscal 2019 from $12.6 million in the second quarter of fiscal 2018. The increase was due to $0.3 million of higher legal costs, severance expense of $0.2 million related to actions taken to improve the manufacturing variances and a $0.2 million recovery of a bad debt recorded in last year’s second quarter. Operating expenses as a percent of net sales increased to 32.5% in the second quarter of fiscal 2019 from 32.2% in the second quarter of fiscal 2018. 
Net loss during the second quarter of fiscal 2019 was $0.3 million or ($0.02) per diluted common share and ($0.02) per Class B diluted common share as compared to net income, including income from discontinued operations of $1.5 million, of $1.7 million during the second quarter of fiscal 2018, or $0.13 per diluted common share and $0.12 per Class B diluted common share. 
We believe that the existing sources of liquidity, including current cash, will provide sufficient resources to meet known capital requirements and working capital needs through the next twelve months.  
Operating activities used $2.7 million of cash during the first six months of fiscal 2019. We had net income of $0.1 million during the first six months of fiscal 2019, which included non-cash stock-based compensation expense of $0.4 million associated with the issuance of stock option and restricted stock awards, $0.4 million for inventory reserve provisions and depreciation and amortization expense of $1.6 million associated with our property and equipment as well as amortization of our intangible assets. Changes in our operating assets and liabilities resulted in a use of cash of $5.3 million during the first six months of fiscal 2019, net of foreign currency exchange gains and losses, included a decrease of $3.9 million in accounts payable, an increase in inventory of $1.8 million and an increase of $0.3 million in prepaid expenses and other assets, partially offset by an increase in accrued liabilities of $0.6 million. The decrease in our accounts payable was due to timing of payments for some of our larger vendors for both inventory and services. The inventory increase was due to growth in supplying replacement systems and parts to the Healthcare market as well as an increase in components for the production of the ALTA 750 TM CT Tube. 
Operating activities used $2.3 million of cash during the first six months of fiscal 2018. We had net income of $1.6 million during the first six months of fiscal 2018, which included non-cash stock-based compensation expense of $0.3 million associated with the issuance of stock option and restricted stock awards and depreciation and amortization expense of $1.5 million associated with our property and equipment as well as amortization of our intangible assets. Changes in our operating assets and liabilities during the first six months of fiscal 2018, net of foreign currency exchange gains and losses, included an increase in inventories of $4.6 million, a decrease of $1.0 million in accounts payable and an increase in prepaid expenses and other assets of $0.6 million. The inventory increase was due to the ongoing growth of our RF and power technologies business, increase in raw material and work in process supporting the semiconductor capital equipment market and growth in supplying replacement systems and parts to the Healthcare market. The decrease in our accounts payable was due to timing of payments for some of our larger vendors for both inventory and services. 
The cash flow used in investing activities consisted primarily of purchases of investments and capital expenditures. 
All future payments of dividends are at the discretion of the Board of Directors. Dividend payments will depend on earnings, capital requirements, operating conditions and such other factors that the Board may deem relevant. 
ITEM 2.  
On January 9, 2019, we issued a press release reporting results for our second quarter ended December 1, 2018, and the declaration of a cash dividend. A copy of the press release is furnished as Exhibit 99.1 to this Form 10-Q and incorporated by reference herein. 
